Chimerix
treatment post infection protected mice from body weight loss and clinical symptoms of disease | Chimerix
Company
Deck Type
Sector
Industry
Deck date
March 2022
Slide
10 of 12
Related slides by other companies
MindMed
Investor Presentation
June 2023
business highlights a leader in developing product candidates to treat brain health disorders diversified pipeline of clinical programs targeting significant unmet medical needs and strategies intended to maximize market exclusivity and protection in drug and digital medicine development and commercialization expected cash runway through key clinical and into first half of tartrate for the treatment of gad and or for the treatment of core symptoms of | MindMed
Ocuphire Pharma
Results
October 2022
oral treatments in clinical development | Ocuphire Pharma
MindMed
Investor Presentation
August 2023
business highlights a leader in developing product candidates to treat brain health disorders diversified pipeline of clinical programs targeting significant unmet medical needs and strategies intended to maximize market exclusivity and in drug and digital medicine development and commercialization expected cash runway through key clinical and into tartrate for the treatment of gad and or for the treatment of core symptoms of | MindMed
Arbutus Biopharma
Results
November 2022
demonstrates target engagement in cells in a mouse model | Arbutus Biopharma
Other recent decks by Chimerix
See all presentations (6 decks)
Investor Presentation
August 2023
Investor Presentation
May 2023
Investor Presentation
March 2023
Investor Conference
November 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights